|
1) Fukata Y, Amano M, Kaibuchi K. Rho-Rho-kinase pathway in smooth muscle contraction and cytoskeletal reorganization of non-muscle cells. Trends Pharmacol Sci. 2001; 22: 32-9
|
|
|
|
2) Oka M, Fagan KA, McMurtry IF, et al. Therapeutic potential of RhoA/Rho kinase inhibitors in pulmonary hypertension. Br J Pharmacol. 2008; 155: 444-54
|
|
|
|
|
|
3) Homma N, McMurtry IF, Oka M, et al. Endothelin-1 and serotonin are involved in activation of RhoA/Rho kinase signaling in the chronically hypoxic hypertensive rat pulmonary circulation. J Cardiovasc Pharmacol. 2007; 50: 697-702
|
|
|
|
|
|
4) Takemoto M, Shimokawa H, Liao JK, et al. Rho-kinase mediates hypoxia-induced downregulation of endothelial nitric oxide synthase. Circulation. 2002; 106: 57-62
|
|
|
|
|
|
5) Matsumoto Y, Uwatoku T, Shimokawa H, et al. Long-term inhibition of Rho-kinase suppresses neointimal formation after stent implantation in porcine coronary arteries: involvement of multiple mechanisms. Arterioscler Thromb Vasc Biol. 2004; 24: 181-6
|
|
|
|
|
|
6) Sawada N, Itoh H, Nakao K, et al. Inhibition of rho-associated kinase results in suppression of neointimal formation of balloon-injured arteries. Circulation. 2000; 101: 2030-3
|
|
|
|
|
|
7) Shimokawa H, Takeshita A. Rho-kinase is an important therapeutic target in cardiovascular medicine. Arterioscler Thromb Vasc Biol. 2005; 25: 1767-75
|
|
|
|
|
|
8) Kozai T, Eto M, Lüscher TF, et al. Statins prevent pulsatile stretch-induced proliferation of human saphenous vein smooth muscle cells via inhibition of Rho/Rho-kinase pathway. Cardiovasc Res. 2005; 68: 475-82
|
|
|
|
|
|
9) Li M, Liu Y, Toksoz D, et al. Inhibition of serotonin-induced mitogenesis, migration, and ERK MAPK nuclear translocation in vascular smooth muscle cells by atorvastatin. Am J Physiol Lung Cell Mol Physiol. 2007; 293: L463-71
|
|
|
|
|
|
10) Uehata M, Ishizaki T, Narumiya S, et al. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature. 1997; 389: 90-4
|
|
|
|
|
|
11) Masumoto A, Hirooka Y, Takeshita A, et al. Possible involvement of Rho-kinase in the pathogenesis of hypertension in humans. Hypertension. 2001; 38: 1307-10
|
|
|
|
|
|
12) Shimokawa H, Hiramori K, Kato K, et al. Anti-anginal effect of fasudil, a Rho-kinase inhibitor, in patients with stable effort angina: a multicenter study. J Cardiovasc Pharmacol. 2002; 40: 751-61
|
|
|
|
|
|
13) Shibuya M, Hirai S, Ohtomo E, et al. Effects of fasudil in acute ischemic stroke: results of a prospective placebo-controlled double-blind trial. J Neurol Sci. 2005; 238: 31-9
|
|
|
|
|
|
14) Robertson TP, Dipp M, Evans AM, et al. Inhibition of sustained hypoxic vasoconstriction by Y-27632 in isolated intrapulmonary arteries and perfused lung of the rat. Br J Pharmacol. 2000; 131: 5-9
|
|
|
|
|
|
15) Nagaoka T, McMurtry I, Oka M, et al. Rho/Rho kinase signaling mediates increased basal pulmonary vascular tone in chronically hypoxic rats. Am J Physiol Lung Cell Mol Physiol. 2004; 287: L665-72
|
|
|
|
|
|
16) Jiang BH, Tawara S, Shimokawa H, et al. Acute vasodilator effect of fasudil, a Rho-kinase inhibitor, in monocrotaline-induced pulmonary hypertension in rats. J Cardiovasc Pharmacol. 2007; 49: 85-9
|
|
|
|
|
|
17) Nagaoka T, McMurtry IF, Oka M, et al. Inhaled Rho kinase inhibitors are potent and selective vasodilators in rat pulmonary hypertension. Am J Respir Crit Care Med. 2005; 171: 494-9
|
|
|
|
|
|
18) Oka M, Homma N, McMurtry IF, et al. Rho kinase-mediated vasoconstriction is important in severe occlusive pulmonary arterial hypertension in rats. Circ Res. 2007; 100: 923-9
|
|
|
|
|
|
19) Abe K, Shimokawa H, Takeshita A, et al. Long-term treatment with a Rho-kinase inhibitor improves monocrotaline-induced fatal pulmonary hypertension in rats. Circ Res. 2004; 94: 385-93
|
|
|
|
|
|
20) Fagan KA, Oka M, McMurtry IF, et al. Attenuation of acute hypoxic pulmonary vasoconstriction and hypoxic pulmonary hypertension in mice by inhibition of Rho-kinase. Am J Physiol Lung Cell Mol Physiol. 2004; 287: L656-64
|
|
|
|
|
|
21) Nagaoka T, McMurtry IF, Oka M, et al. Involvement of RhoA/Rho kinase signaling in pulmonary hypertension of the fawn-hooded rat. J Appl Physiol. 2006; 100: 996-1002
|
|
|
|
|
|
22) Homma N, McMurtry IF, Oka M, et al. Involvement of RhoA/Rho kinase signaling in protection against monocrotaline-induced pulmonary hypertension in pneumonectomized rats by dehydroepiandrosterone. Am J Physiol Lung Cell Mol Physiol. 2008; 295: L71-8
|
|
|
|
|
|
23) Tawara S, Fukumoto Y, Shimokawa H. Effects of combined therapy with a Rho-kinase inhibitor and prostacyclin on monocrotaline-induced pulmonary hypertension in rats. J Cardiovasc Pharmacol. 2007; 50: 195-200
|
|
|
|
|
|
24) Ishikura K, Yamada N, Nakano T, et al. Beneficial acute effects of rho-kinase inhibitor in patients with pulmonary arterial hypertension. Circ J. 2006; 70: 174-8
|
|
|
|
|
25) Fukumoto Y, Matoba T, Shimokawa H, et al. Acute vasodilator effects of a Rho-kinase inhibitor, fasudil, in patients with severe pulmonary hypertension. Heart. 2005; 91: 391-2
|
|
|
|
|
|
26) Fujita H, Fukumoto Y, Shimokawa H, et al. Acute vasodilator effects of inhaled fasudil, a specific Rho-kinase inhibitor, in patients with pulmonary arterial hypertension. Heart Vessels. 2010; 25: 144-9
|
|
|
|
|
|
27) Li F, Xia W, Yuan S, Sun R. Acute inhibition of Rho-kinase attenuates pulmonary hypertension in patients with congenital heart disease. Pediatr Cardiol. 2009; 30: 363-6
|
|
|
|
|
|
28) Do e Z, Fukumoto Y, Shimokawa H, et al. Evidence for Rho-kinase activation in patients with pulmonary arterial hypertension. Circ J. 2009; 73: 1731-9
|
|
|
|
|